Top Page
Epsilon Healthcare Limited
(Sydney:EPN)
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
Epsilon Healthcare Limited Business Overview & Revenue Model
Epsilon Healthcare Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.60M | 6.65M | 7.11M | 5.50M | 7.36M |
| Gross Profit | 4.17M | 4.81M | -3.09M | 2.06M | 2.66M |
| EBITDA | -2.13M | -1.31M | -10.86M | -8.09M | -9.20M |
| Net Income | -3.25M | -1.09M | -13.29M | -8.91M | -10.95M |
Balance Sheet | |||||
| Total Assets | 22.26M | 14.41M | 20.50M | 30.55M | 37.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.57M | 343.01K | 861.99K | 2.34M | 6.97M |
| Total Debt | 7.88M | 3.45M | 3.20M | 4.33M | 5.11M |
| Total Liabilities | 11.57M | 6.87M | 11.23M | 10.98M | 11.94M |
| Stockholders Equity | 10.70M | 7.54M | 9.27M | 19.57M | 25.32M |
Cash Flow | |||||
| Free Cash Flow | -3.50M | -803.47K | -3.10M | -6.18M | -9.93M |
| Operating Cash Flow | -3.41M | -703.37K | -2.57M | -5.43M | -8.69M |
| Investing Cash Flow | -97.73K | -99.12K | -529.40K | -737.59K | -1.73M |
| Financing Cash Flow | 4.73M | 335.91K | 1.61M | 1.47M | 14.60M |
Epsilon Healthcare Limited Technical Analysis
Epsilon Healthcare Limited Peers Comparison
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare Limited has confirmed that all resolutions put to shareholders at its latest Annual General Meeting were passed by poll, signaling solid shareholder backing for the company’s current strategy and governance. The board highlighted the outcome as a vote of confidence from investors, which may support continuity in its diversified healthcare, pharmaceutical manufacturing, and pharmacy services operations as it pursues its broader growth objectives.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has had its securities reinstated to quotation on the ASX following a suspension and its emergence from voluntary administration in June 2024, after satisfying the exchange’s conditions. The company has undertaken an extensive internal overhaul of its operations, financial position, governance and disclosure practices, which the board and management say has stabilised the business, rebuilt stakeholder confidence and positioned Epsilon to pursue a disciplined and sustainable growth strategy. Over the next 12 months, Epsilon plans to scale its core capabilities in manufacturing, pharmacy and clinical services, develop new products and services, leverage its GMP infrastructure for scalable growth, expand its clinical and pharmacy offerings, and seek strategic opportunities to diversify revenue and strengthen operational resilience. The board also continues a professionally guided legal, forensic and financial review of historical matters involving former directors to ensure shareholder and company interests are protected and, where appropriate, remediated, underscoring a renewed emphasis on governance, transparency and long-term shareholder value.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has had its securities reinstated to trading on the ASX, with the exchange confirming that the company has met all required conditions for quotation to resume. The lifting of the trading suspension, effective from the start of trading on 19 December 2025, restores market liquidity for shareholders and signals regulatory confidence in the company’s compliance status.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has announced its progress towards the reinstatement of its securities on the Australian Securities Exchange following a suspension period. The company has conducted a thorough review of its operations, governance, and financial standing to ensure transparency and compliance, positioning itself for a sustainable growth strategy upon reinstatement. EPN confirms no material information is outstanding, aligning its operations with ASX regulations and maintaining readiness to meet future investor expectations.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited announced measures to reinforce its working capital position, including a $2,000,000 loan facility from its Managing Director, deferral of repayment deadlines for loans and fees owed to directors until 2027, and adjustment of obligations for management salaries and incentives. These actions, underscored by significant contributions from the leadership, reflect strong confidence in the company’s future prospects and enhance its financial stability to support ongoing operations and stakeholder interests.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited reported a 19% increase in revenue to $3.4 million for the half-year ending June 2025, driven by new client engagements and the successful launch of Epsilon Pharmacy. Despite the revenue growth, the company experienced a net loss of $2.07 million, attributed to administrative fees, interest, and loan charges, as well as costs associated with remediation work due to voluntary administration.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has announced a change in its external auditor, appointing RSM Australia effective December 16, 2025. This decision is part of the company’s commitment to strong corporate governance and aligning its audit framework with operational needs and strategic growth objectives, following the resignation of A D Danieli Audit with ASIC’s consent.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has announced its Annual General Meeting (AGM) scheduled for December 22, 2025, in Brisbane. The meeting will address key resolutions including the adoption of the remuneration report, re-election of Mr. Alan Beasley as a director, and approval of a 10% placement capacity. These resolutions are significant for the company’s governance and financial strategy, potentially impacting shareholder value and corporate operations. The directors have recommended voting in favor of the resolutions, which aim to align the company’s policies with shareholder interests and market regulations.
Epsilon Healthcare Limited has released its corporate governance statement for the financial year ending December 31, 2024, which has been approved by the board as of November 18, 2025. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, ensuring transparency and compliance in its operations. This announcement underscores Epsilon Healthcare’s commitment to maintaining high governance standards, which is crucial for its stakeholders and enhances its industry positioning.
Epsilon Healthcare Limited has released its Annual Report for 2024, detailing its financial performance and strategic initiatives. The report highlights the company’s efforts to strengthen its market position and improve operational efficiencies, which could have significant implications for its stakeholders.
Epsilon Healthcare Limited reported a record-breaking quarter with customer receipts reaching $2.919 million, marking a 126% year-on-year growth. This significant financial performance highlights the company’s successful turnaround and strategic growth following its emergence from voluntary administration in mid-2024. The expansion of Epsilon’s pharmacy operations and the sale and leaseback of its Southport property have improved financial flexibility, positioning the company for continued growth and profitability. The company’s divisions, including Epsilon Pharma, Epsilon Clinics, and the newly launched Epsilon Pharmacy, have all contributed to this robust performance, showcasing Epsilon’s integrated healthcare ecosystem and its commitment to quality and patient care.
Epsilon Healthcare Limited reported significant revenue growth and improved financial performance for the quarter ending June 2025, marking a pivotal point in its recovery and growth trajectory. The company has seen substantial growth in contract manufacturing activities, a successful launch of its pharmacy operations, and consistent performance from its clinics, positioning it for sustained growth and long-term value creation.
Epsilon Healthcare Limited has announced its quarterly activities report for the period ending March 31, 2025, highlighting strategic growth and operational improvements. The company has commenced operations at Epsilon Pharmacy, extended a $4.8 million loan facility, and effectuated a deed of company arrangement for Epsilon Clinics. These developments are part of Epsilon’s strategy to build an integrated healthcare ecosystem, enhance medicine accessibility, and improve financial performance and shareholder value.
Epsilon Healthcare Limited reported a significant downturn in its financial performance for the year ended December 31, 2024. The company experienced a 16% decline in revenue from ordinary activities, amounting to $5,600,181, and a substantial increase in net loss, which rose by 198% to $3,246,325. No dividends were declared for the period, reflecting the challenging financial situation. This downturn may impact the company’s operations and market positioning, raising concerns among stakeholders about future profitability and strategic direction.